Nordic Nanovector states commitment to oncology development with its Betalutin program

Norwegian biotech company Nordic Nanovector has stated its commitment to becoming a “significant player” in oncology and hematology at an investors’ and analysts’ day.

Its lead product, Betalutin, is a potential new treatment for non-Hodgkin’s lymphoma, which has a high unmet need and a market estimated to exceed $12 billion by 2018. There is promising data from preclinical and clinical studies with Betalutin in non-Hodgkin’s lymphoma patients, with an ongoing Phase I/II trial showing an overall response rate of 64% and a complete response of 36%. The company says one of Betalutin’s key features is its ability to target and selectively kill tumor cells by delivering a radioactive payload directly to cancer cells and the local tumor environment.

Nordic Nanovector targets first regulatory submission for the therapy as a third line treatment for patients with follicular lymphoma in the first half of 2019. A range of protective pre-dosing regimens are being evaluated in the ongoing Phase I/II study to ensure an optimal pre-dosing and treatment regimen is used in the pivotal Phase II PARADIGME study, which is intended to form the basis of this regulatory submission.